Pluristem Selects Fisher BioServices as Worldwide Dispatch Distributor of Its PLX Cell Therapies to Serve Global Clinical Studies Pluristem Therapeutics, Inc. announced it has selected Fisher BioServices, Inc. as worldwide dispatch distributor of its off-the-shelf PLacental eXpanded (PLX) cells. Fisher BioServices will provide cryogenic storage and distribution of Pluristem’s PLX cells for its clinical trials and preclinical sites around the world. [Pluristem Therapeutics, Inc.] Press Release Stem Cell-Modifying Antibodies for Regenerative Therapies Stem cell therapeutics firm Medistem and Superview Biotechnology signed a collaboration centered on the use of Medistem’s stem cell lines to screen for monoclonal antibodies with potential in regenerative medicine. The aim of the collaboration is to identify monoclonal antibodies that modulate the activity of stem cells that are already present in the body, in effect, taking an alternative tack to approaches based on developing stem cells-derived therapeutics. [Genetic Engineering & Biotechnology News] Press Release Power of the Dream Ventures Acquires Genetic Immunity Power of the Dream Ventures, Inc. announced the acquisition of Genetic Immunity, Inc. a Phase III clinical stage biotech company with experimental nanomedicines that will lead to the next generation of immunotherapies in a market that that is projected to reach $11.00 billion by 2018. [Genetic Immunity, Inc.] Press Release Cytori Awarded Contract Valued up to $106 Million by Biomedical Advanced Research and Development Authority (BARDA) to Develop Cell Therapies for Thermal Burns Combined with Radiation Injury Cytori Therapeutics has been awarded a contract that may be valued up to $106 million by the U.S. Department of Health and Human Service’s BARDA, if all Contract Options are executed. The Contract is for preclinical and clinical development of the Company’s cell therapy for the treatment of thermal burns combined with radiation injury. [Cytori Therapeutics Inc.] Press Release Carnegie Mellon’s Adam W. Feinberg Wins Prestigious Innovation Award from National Institutes of Health Carnegie Mellon University’s Adam W. Feinberg was awarded a five-year, $2.25 million National Institutes of Health Director’s New Innovator Award to continue developing new biomaterials and cardiac tissue engineering strategies to help repair the human heart following injury and disease. [PR Newswire Association LLC] Press Release Vital Therapies, Inc. Announces First Closing of $76 Million Staged Financing to Fund Phase III Pivotal Clinical Trial of ELAD® in USA and EU Vital Therapies, Inc. announced the first closing of $16 million from a multi-stage commitment to invest $76 million in the company led by Vital Therapies’ existing private investors. The investment is designed to fund three pivotal phase III trials of the company’s bio-artificial liver therapy, ELAD, in two specific forms of acute liver failure. [Vital Therapies, Inc.] Press Release Animal Cell Therapies Announces $1.5 million Developmental Work in Canine Orthopedic Product Line Animal Cell Therapies, Inc. announced the commitment of $1.5 million to develop a proprietary line of canine orthopedic products called PROTECT. The dedicated funds will allow Animal Cell Therapies, in partnership with leading researchers, to fully develop the PROTECT Cell Therapy product portfolio. [Animal Cell Therapies, Inc.] Press Release Osiris Therapeutics Regains Worldwide Rights to Prochymal and Chondrogen Osiris Therapeutics, Inc. announced the conclusion of its collaboration with Genzyme, a Sanofi company. As the Collaboration Agreement is now ended, all rights to Prochymal® and ChondrogenTM worldwide revert back to Osiris. [Osiris Therapeutics, Inc.] Press Release TiGenix’s New European Production Facility Obtains EMA Approval for Commercial Production of ChondroCelect TiGenix announced that after the successful cGMP inspection by the Dutch authorities, it has obtained the crucial approval from the European Medicines Agency (EMA) for the production of ChondroCelect, the company’s commercial cell therapy product for cartilage repair in the knee, in its new state-of-the-art manufacturing facility in Sittard Geleen. [TiGenix NV] Press Release New Edition of Definitive (Two-Volume) Resource in Stem Cells Released Advanced Cell Technology, Inc. announced that its chief scientific officer, Robert Lanza, M.D. and Anthony Atala, M.D. have released the second edition of Handbook of Stem Cells (Academic Press/Elsevier), the widely-recognized definitive resource in the field of stem cells. [Advanced Cell Technology, Inc.] Press Release |